Market closed
Galectin Therapeutics/$GALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Ticker
$GALT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15
Website
GALT Metrics
BasicAdvanced
$90M
-
-$0.76
0.69
-
Price and volume
Market cap
$90M
Beta
0.69
52-week high
$3.78
52-week low
$0.73
Average daily volume
258K
Financial strength
Current ratio
0.487
Quick ratio
0.427
Long term debt to equity
-82.574
Total debt to equity
-103.08
Interest coverage (TTM)
-7.66%
Management effectiveness
Return on assets (TTM)
-116.08%
Return on equity (TTM)
57.62%
Valuation
Price to book
-0.85
Price to tangible book (TTM)
-0.85
Price to free cash flow (TTM)
-2.118
Growth
Earnings per share change (TTM)
1.71%
3-year earnings per share growth (CAGR)
13.03%
What the Analysts think about GALT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
GALT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GALT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
GALT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Galectin Therapeutics stock?
Galectin Therapeutics (GALT) has a market cap of $90M as of April 26, 2025.
What is the P/E ratio for Galectin Therapeutics stock?
The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of April 26, 2025.
Does Galectin Therapeutics stock pay dividends?
No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of April 26, 2025.
When is the next Galectin Therapeutics dividend payment date?
Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Galectin Therapeutics?
Galectin Therapeutics (GALT) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.